A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 616M | 616M | 329M | 234M | - | - |
| Net Income | 447M | 447M | 23M | 13M | -224M | -348M |
| EPS | $2.77 | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 |
| Free Cash Flow | -25M | -25M | -41M | -31M | -176M | -296M |
| ROIC | 50.0% | 65.7% | 36.8% | 37.2% | -103.2% | -83.8% |
| Gross Margin | 83.7% | 83.7% | 88.3% | 94.0% | - | - |
| Debt/Equity | 0.39 | 0.39 | 1.14 | 0.69 | 1.42 | 0.33 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 123M | 123M | 42M | 21M | -218M | -345M |
| Operating Margin | 20.0% | 20.0% | 12.7% | 8.8% | - | - |
| ROE | 69.0% | 102.8% | 12.2% | 11.6% | -151.4% | -92.0% |
| Shares Outstanding | 161M | 161M | 156M | 141M | 136M | 132M |
TG THERAPEUTICS, INC. passes 4 of 9 quality checks, suggesting mixed fundamentals.
TG THERAPEUTICS, INC. trades at 12.5x trailing earnings, compared to its 15-year median P/E of 11.1x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average gross margin is 88.6%. Total shareholder yield (buybacks) is 1.6%. At current prices, the estimated annualized return to fair value is +105.9%.
TG THERAPEUTICS, INC. (TGTX) has a current P/E ratio of 12.5, compared to its historical median P/E of 11.1. The stock is currently considered Expensive based on its historical valuation range.
TG THERAPEUTICS, INC. (TGTX) has a 5-year average return on invested capital (ROIC) of -9.4%. This is below average and may indicate limited pricing power.
TG THERAPEUTICS, INC. (TGTX) has a market capitalization of $5.6B. It is classified as a mid-cap stock.
TG THERAPEUTICS, INC. (TGTX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.64%.
Based on historical P/E analysis, TG THERAPEUTICS, INC. (TGTX) appears expensive. The current P/E of 12.5 is 12% above its historical median of 11.1. The estimated fair value CAGR (P/E method) is 105.9%.
TG THERAPEUTICS, INC. (TGTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
TG THERAPEUTICS, INC. (TGTX) reported annual revenue of $616 million in its most recent fiscal year, based on SEC EDGAR filings.
TG THERAPEUTICS, INC. (TGTX) has a net profit margin of 72.6%. This is a strong margin indicating high profitability.
TG THERAPEUTICS, INC. (TGTX) generated $-25 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
TG THERAPEUTICS, INC. (TGTX) has a debt-to-equity ratio of 0.39. This indicates a conservatively financed balance sheet.
TG THERAPEUTICS, INC. (TGTX) reported earnings per share (EPS) of $2.77 in its most recent fiscal year.
TG THERAPEUTICS, INC. (TGTX) has a return on equity (ROE) of 102.8%. This indicates the company generates strong returns for shareholders.
TG THERAPEUTICS, INC. (TGTX) has a 5-year average gross margin of 88.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for TG THERAPEUTICS, INC. (TGTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TG THERAPEUTICS, INC. (TGTX) has a book value per share of $4.01, based on its most recent annual SEC filing.